<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>BloodðŸ©¸Doctor | ELN 2025 CML Deep Dive</title>
    <link rel="preconnect" href="https://fonts.googleapis.com" />
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
    <link
      href="https://fonts.googleapis.com/css2?family=Fraunces:opsz,wght@9..144,500;9..144,600;9..144,700&family=Manrope:wght@300;400;500;600;700&display=swap"
      rel="stylesheet"
    />
    <style>
      :root {
        --ink: #101018;
        --night: #1a1b22;
        --blood: #9b0b1f;
        --rose: #e25b6c;
        --ember: #ffb199;
        --ivory: #fbf7f3;
        --sand: #f2e7de;
        --sage: #cfe5dc;
        --sky: #e8f1f6;
        --slate: #353847;
        --shadow: 0 20px 50px rgba(16, 16, 24, 0.18);
        --radius: 22px;
      }

      * {
        box-sizing: border-box;
      }

      body {
        margin: 0;
        font-family: "Manrope", system-ui, -apple-system, sans-serif;
        color: var(--ink);
        background: radial-gradient(circle at top, #ffffff 0%, #f7efe8 40%, #efe3d7 100%);
      }

      a {
        color: inherit;
        text-decoration: none;
      }

      button {
        font-family: inherit;
      }

      .page {
        min-height: 100vh;
        display: flex;
        flex-direction: column;
      }

      .hero {
        position: relative;
        padding: 44px 6vw 72px;
        overflow: hidden;
      }

      .hero::before,
      .hero::after {
        content: "";
        position: absolute;
        border-radius: 999px;
        opacity: 0.8;
        z-index: 0;
      }

      .hero::before {
        width: 420px;
        height: 420px;
        background: radial-gradient(circle, rgba(226, 91, 108, 0.45) 0%, rgba(226, 91, 108, 0) 70%);
        right: -140px;
        top: -180px;
      }

      .hero::after {
        width: 360px;
        height: 360px;
        background: radial-gradient(circle, rgba(207, 229, 220, 0.6) 0%, rgba(207, 229, 220, 0) 70%);
        left: -120px;
        bottom: -160px;
      }

      .nav {
        display: flex;
        align-items: center;
        justify-content: space-between;
        position: relative;
        z-index: 1;
        gap: 20px;
      }

      .brand {
        font-size: 1.4rem;
        font-weight: 700;
      }

      .nav-cta {
        display: flex;
        align-items: center;
        gap: 12px;
        font-weight: 600;
        color: rgba(16, 16, 24, 0.7);
      }

      .hero-grid {
        margin-top: 56px;
        display: grid;
        grid-template-columns: repeat(2, minmax(0, 1fr));
        gap: 40px;
        align-items: center;
        position: relative;
        z-index: 1;
      }

      .hero-copy h1 {
        font-family: "Fraunces", serif;
        font-size: clamp(2.5rem, 4vw, 4.1rem);
        line-height: 1.05;
        margin: 0 0 16px;
      }

      .hero-copy p {
        font-size: 1.05rem;
        line-height: 1.7;
        color: rgba(16, 16, 24, 0.72);
        margin: 0 0 24px;
      }

      .eyebrow {
        display: inline-flex;
        align-items: center;
        gap: 8px;
        padding: 8px 14px;
        border-radius: 999px;
        background: var(--ivory);
        font-weight: 600;
        font-size: 0.85rem;
        margin-bottom: 12px;
      }

      .cta-row {
        display: flex;
        align-items: center;
        gap: 16px;
        flex-wrap: wrap;
      }

      .cta-primary {
        background: var(--blood);
        color: #fff;
        border: none;
        padding: 16px 32px;
        border-radius: 999px;
        font-weight: 600;
        font-size: 1rem;
        cursor: pointer;
        box-shadow: 0 18px 40px rgba(155, 11, 31, 0.25);
        transition: transform 0.2s ease, box-shadow 0.2s ease;
      }

      .cta-primary:hover {
        transform: translateY(-2px);
        box-shadow: 0 22px 44px rgba(155, 11, 31, 0.3);
      }

      .cta-secondary {
        font-weight: 600;
        color: rgba(16, 16, 24, 0.65);
      }

      .hero-panel {
        background: #fff;
        border-radius: var(--radius);
        padding: 26px;
        box-shadow: var(--shadow);
        display: grid;
        gap: 18px;
      }

      .hero-panel img {
        width: 100%;
        border-radius: 18px;
        display: block;
      }

      .quick-stats {
        display: grid;
        gap: 14px;
      }

      .stat-row {
        display: flex;
        justify-content: space-between;
        align-items: center;
        padding: 14px 16px;
        border-radius: 14px;
        background: var(--sky);
      }

      .stat-row strong {
        font-family: "Fraunces", serif;
        font-size: 1.2rem;
      }

      .chips {
        display: flex;
        gap: 10px;
        flex-wrap: wrap;
      }

      .chip {
        padding: 8px 12px;
        border-radius: 999px;
        background: var(--sand);
        font-size: 0.85rem;
        font-weight: 600;
      }

      .section {
        padding: 56px 6vw;
      }

      .section-title {
        font-family: "Fraunces", serif;
        font-size: clamp(1.9rem, 3vw, 2.6rem);
        margin: 0 0 16px;
      }

      .section-sub {
        color: rgba(16, 16, 24, 0.7);
        line-height: 1.7;
        max-width: 820px;
        margin-bottom: 32px;
      }

      .app {
        background: var(--ivory);
        border-radius: 32px;
        padding: 32px;
        box-shadow: var(--shadow);
      }

      .app.is-hidden {
        display: none;
      }

      .control-bar {
        display: flex;
        flex-wrap: wrap;
        align-items: center;
        gap: 14px;
        margin-bottom: 28px;
      }

      .toggle {
        padding: 10px 18px;
        border-radius: 999px;
        border: 1px solid rgba(16, 16, 24, 0.15);
        background: #fff;
        font-weight: 600;
        cursor: pointer;
      }

      .map {
        display: grid;
        grid-template-columns: repeat(4, minmax(0, 1fr));
        gap: 18px;
      }

      .map-card {
        background: #fff;
        border-radius: 18px;
        padding: 18px;
        box-shadow: 0 14px 30px rgba(16, 16, 24, 0.08);
        display: grid;
        gap: 12px;
      }

      .map-card button {
        align-self: start;
        background: transparent;
        border: none;
        color: var(--blood);
        font-weight: 600;
        cursor: pointer;
        padding: 0;
      }

      .module {
        margin-top: 28px;
        background: #fff;
        border-radius: 22px;
        padding: 24px;
        box-shadow: 0 16px 34px rgba(16, 16, 24, 0.1);
        display: grid;
        gap: 18px;
      }

      .module-head {
        display: flex;
        justify-content: space-between;
        align-items: center;
        gap: 12px;
      }

      .module-tag {
        padding: 6px 12px;
        border-radius: 999px;
        background: var(--sand);
        font-weight: 600;
        font-size: 0.8rem;
      }

      .module-grid {
        display: grid;
        grid-template-columns: repeat(2, minmax(0, 1fr));
        gap: 16px;
      }

      .card {
        border-radius: 16px;
        padding: 16px;
        background: var(--sky);
        display: grid;
        gap: 8px;
      }

      .card h4 {
        margin: 0;
        font-size: 1rem;
      }

      .card p,
      .card ul {
        margin: 0;
        color: rgba(16, 16, 24, 0.75);
        line-height: 1.6;
      }

      .card ul {
        padding-left: 18px;
      }

      .deep {
        background: #fff5f4;
      }

      body.simplify .deep {
        display: none;
      }

      .check {
        background: var(--ivory);
        border-radius: 16px;
        padding: 16px;
        display: grid;
        gap: 10px;
      }

      .reveal {
        align-self: start;
        background: transparent;
        border: 1px solid rgba(16, 16, 24, 0.2);
        padding: 8px 14px;
        border-radius: 999px;
        cursor: pointer;
        font-weight: 600;
      }

      .answer {
        display: none;
        color: rgba(16, 16, 24, 0.8);
      }

      .answer.active {
        display: block;
      }

      .table-wrap {
        overflow-x: auto;
      }

      table {
        width: 100%;
        border-collapse: collapse;
        font-size: 0.95rem;
      }

      th,
      td {
        text-align: left;
        padding: 10px 12px;
        border-bottom: 1px solid rgba(16, 16, 24, 0.12);
      }

      th {
        color: var(--slate);
        font-weight: 700;
      }

      .cta-band {
        background: var(--night);
        color: #fff;
        border-radius: 26px;
        padding: 30px;
        display: flex;
        justify-content: space-between;
        align-items: center;
        gap: 20px;
        margin-top: 32px;
      }

      .cta-band p {
        margin: 0;
        color: rgba(255, 255, 255, 0.7);
      }

      .footer {
        padding: 24px 6vw 40px;
        display: flex;
        flex-wrap: wrap;
        justify-content: space-between;
        gap: 12px;
        color: rgba(16, 16, 24, 0.7);
        font-size: 0.95rem;
      }

      .disclaimer {
        font-size: 0.85rem;
        color: rgba(16, 16, 24, 0.6);
        margin-top: 12px;
      }

      @media (max-width: 1100px) {
        .hero-grid,
        .module-grid {
          grid-template-columns: 1fr;
        }

        .map {
          grid-template-columns: repeat(2, minmax(0, 1fr));
        }

        .cta-band {
          flex-direction: column;
          align-items: flex-start;
        }

        .nav-cta {
          display: none;
        }
      }

      @media (max-width: 700px) {
        .map {
          grid-template-columns: 1fr;
        }
      }

      @media (prefers-reduced-motion: reduce) {
        * {
          animation: none !important;
          transition: none !important;
        }
      }
    </style>
  </head>
  <body>
    <div class="page">
      <header class="hero">
        <nav class="nav">
          <div class="brand">BloodðŸ©¸Doctor</div>
          <div class="nav-cta">ELN 2025 CML Deep Dive for Hematology/Oncology</div>
        </nav>

        <div class="hero-grid">
          <div class="hero-copy">
            <div class="eyebrow">Guided learning artefact Â· ELN 2025 CML</div>
            <h1>Master the 2025 ELN CML guidance, end-to-end.</h1>
            <p>
              A clinician-focused, step-by-step learning flow that covers diagnosis, risk stratification, response
              milestones, treatment sequencing, TFR, pregnancy, adverse events, and transplant decisions.
            </p>
            <div class="cta-row">
              <button class="cta-primary" id="startLearning">Start the deep dive</button>
              <span class="cta-secondary">Single click to open the full learning pathway.</span>
            </div>
            <div class="chips">
              <span class="chip">Complete guidance coverage</span>
              <span class="chip">High-yield tables</span>
              <span class="chip">Actionable clinical flow</span>
            </div>
          </div>
          <div class="hero-panel">
            <img
              alt="Clinical learning dashboard"
              src="https://images.unsplash.com/photo-1559757175-5700dde675bc?auto=format&fit=crop&w=1000&q=80"
            />
            <div class="quick-stats">
              <div class="stat-row">
                <span>Modules</span>
                <strong>12</strong>
              </div>
              <div class="stat-row">
                <span>Focus</span>
                <strong>ELN 2025</strong>
              </div>
              <div class="stat-row">
                <span>Use case</span>
                <strong>Teaching + practice</strong>
              </div>
            </div>
          </div>
        </div>
      </header>

      <section class="section" id="app">
        <div class="app is-hidden" id="learningApp">
          <div class="control-bar">
            <strong>View controls:</strong>
            <button class="toggle" id="simplifyToggle" aria-pressed="false">Simplify view</button>
            <span class="cta-secondary">Hide deep-dive panels if you want a fast recap.</span>
          </div>

          <div class="section-title">Learning map</div>
          <div class="section-sub">
            Follow the ELN 2025 path from diagnosis to long-term management. Each module has core guidance and a deep
            dive panel for nuance.
          </div>

          <div class="map">
            <div class="map-card">
              <strong>Module 1</strong>
              <div>What changed in ELN 2025</div>
              <button data-target="#module-1">Open module</button>
            </div>
            <div class="map-card">
              <strong>Module 2</strong>
              <div>Diagnosis and baseline testing</div>
              <button data-target="#module-2">Open module</button>
            </div>
            <div class="map-card">
              <strong>Module 3</strong>
              <div>Classification and risk</div>
              <button data-target="#module-3">Open module</button>
            </div>
            <div class="map-card">
              <strong>Module 4</strong>
              <div>Monitoring and response definitions</div>
              <button data-target="#module-4">Open module</button>
            </div>
            <div class="map-card">
              <strong>Module 5</strong>
              <div>Milestones and response categories</div>
              <button data-target="#module-5">Open module</button>
            </div>
            <div class="map-card">
              <strong>Module 6</strong>
              <div>First-line therapy selection</div>
              <button data-target="#module-6">Open module</button>
            </div>
            <div class="map-card">
              <strong>Module 7</strong>
              <div>Resistance and mutation-guided therapy</div>
              <button data-target="#module-7">Open module</button>
            </div>
            <div class="map-card">
              <strong>Module 8</strong>
              <div>Second-line and beyond</div>
              <button data-target="#module-8">Open module</button>
            </div>
            <div class="map-card">
              <strong>Module 9</strong>
              <div>Advanced phase and blast crisis</div>
              <button data-target="#module-9">Open module</button>
            </div>
            <div class="map-card">
              <strong>Module 10</strong>
              <div>Allogeneic transplant</div>
              <button data-target="#module-10">Open module</button>
            </div>
            <div class="map-card">
              <strong>Module 11</strong>
              <div>Treatment-free remission (TFR)</div>
              <button data-target="#module-11">Open module</button>
            </div>
            <div class="map-card">
              <strong>Module 12</strong>
              <div>Pregnancy, parenting, adverse events</div>
              <button data-target="#module-12">Open module</button>
            </div>
          </div>

          <section class="module" id="module-1">
            <div class="module-head">
              <h3>Module 1: What changed in ELN 2025</h3>
              <span class="module-tag">Orientation</span>
            </div>
            <div class="module-grid">
              <div class="card">
                <h4>Core guidance</h4>
                <ul>
                  <li>WHO 2022 reframes CML as a biphasic disease and lowers BP threshold to &gt;=20% blasts.</li>
                  <li>Milestones now framed as favorable, warning, unfavorable (vs optimal/warning/failure).</li>
                  <li>More emphasis on dose reduction for toxicity and individualized switching decisions.</li>
                  <li>TFR data matured, with clearer entry criteria and monitoring schedules.</li>
                </ul>
              </div>
              <div class="card deep">
                <h4>Clinical nuance</h4>
                <p>
                  ELN could not fully endorse either WHO or legacy AP definitions, but recognizes high-risk indicators in CP.
                  Evidence since 2020 drives a more patient-specific approach to switching, particularly in older patients
                  where deep molecular response may not justify higher-toxicity TKI.
                </p>
              </div>
            </div>
          </section>

          <section class="module" id="module-2">
            <div class="module-head">
              <h3>Module 2: Diagnosis and baseline testing</h3>
              <span class="module-tag">Confirm CML</span>
            </div>
            <div class="module-grid">
              <div class="card">
                <h4>Baseline essentials</h4>
                <ul>
                  <li>Diagnosis requires detection of BCR::ABL1 (Ph+ t(9;22)).</li>
                  <li>Marrow morphology + CBA, RT-qPCR on PB or BM.</li>
                  <li>Identify transcript type to enable precise monitoring.</li>
                </ul>
              </div>
              <div class="card deep">
                <h4>Recommended baseline workup (ELN)</h4>
                <div class="table-wrap">
                  <table>
                    <thead>
                      <tr>
                        <th>Domain</th>
                        <th>Key items</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td>Routine labs + exam</td>
                        <td>FBC, biochemistry incl lipid profile, HbA1c, hepatitis B serology, ECG, spleen/liver size</td>
                      </tr>
                      <tr>
                        <td>Cytogenetics</td>
                        <td>CBA for t(9;22) + variants, document ACA at diagnosis</td>
                      </tr>
                      <tr>
                        <td>FISH</td>
                        <td>Useful for screening, variant/cryptic rearrangements</td>
                      </tr>
                      <tr>
                        <td>RT-qPCR</td>
                        <td>Standard diagnostic tool, detect transcript type</td>
                      </tr>
                      <tr>
                        <td>NGS panels</td>
                        <td>Not routine in CP; recommended in BP</td>
                      </tr>
                    </tbody>
                  </table>
                </div>
              </div>
            </div>
            <div class="check">
              <strong>Quick check</strong>
              <div>Why is transcript typing essential at diagnosis?</div>
              <button class="reveal" data-reveal>Show answer</button>
              <div class="answer">It enables accurate molecular monitoring and response assessment.</div>
            </div>
          </section>

          <section class="module" id="module-3">
            <div class="module-head">
              <h3>Module 3: Classification and risk stratification</h3>
              <span class="module-tag">Risk framing</span>
            </div>
            <div class="module-grid">
              <div class="card">
                <h4>Core guidance</h4>
                <ul>
                  <li>ELTS replaces Sokal/Euro/EUTOS for predicting CML-related mortality.</li>
                  <li>WHO 2022: BP if blasts &gt;=20%; AP category removed, high-risk indicators emphasized.</li>
                  <li>High-risk ACA are warning signs and influence monitoring and therapy selection.</li>
                </ul>
              </div>
              <div class="card deep">
                <h4>High-risk indicators (WHO 2022)</h4>
                <ul>
                  <li>Blasts 10â€“19%, PB basophils &gt;=20%.</li>
                  <li>High ELTS score.</li>
                  <li>ACA: 3q26.2 rearrangements, -7, i(17q), complex karyotype.</li>
                  <li>Clusters of small megakaryocytes with fibrosis.</li>
                </ul>
              </div>
            </div>
          </section>

          <section class="module" id="module-4">
            <div class="module-head">
              <h3>Module 4: Monitoring and response definitions</h3>
              <span class="module-tag">Molecular tracking</span>
            </div>
            <div class="module-grid">
              <div class="card">
                <h4>Monitoring cadence</h4>
                <ul>
                  <li>Blood counts every 2 weeks until CHR.</li>
                  <li>RT-qPCR at least every 3 months until MMR confirmed.</li>
                  <li>After stable MMR: every 4â€“6 months.</li>
                  <li>More frequent monitoring if levels rise or fluctuate.</li>
                </ul>
              </div>
              <div class="card deep">
                <h4>Response definitions (International Scale)</h4>
                <div class="table-wrap">
                  <table>
                    <thead>
                      <tr>
                        <th>Response</th>
                        <th>BCR::ABL1IS</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td>CCyR equivalent</td>
                        <td>&lt;= 1%</td>
                      </tr>
                      <tr>
                        <td>MMR</td>
                        <td>&lt;= 0.1%</td>
                      </tr>
                      <tr>
                        <td>MR4</td>
                        <td>&lt;= 0.01%</td>
                      </tr>
                      <tr>
                        <td>MR4.5</td>
                        <td>&lt;= 0.0032%</td>
                      </tr>
                      <tr>
                        <td>MR5</td>
                        <td>&lt;= 0.001%</td>
                      </tr>
                    </tbody>
                  </table>
                </div>
                <p>
                  Atypical transcripts: use personalized RT-qPCR or RT-ddPCR; CBA is insufficient for routine monitoring but
                  is useful when RT-qPCR cannot quantify or when resistance/progression is suspected. FISH can help in rare
                  transcript follow-up.
                </p>
              </div>
            </div>
          </section>

          <section class="module" id="module-5">
            <div class="module-head">
              <h3>Module 5: Milestones and response categories</h3>
              <span class="module-tag">Decision points</span>
            </div>
            <div class="module-grid">
              <div class="card">
                <h4>ELN 2025 categories</h4>
                <ul>
                  <li>Favorable: switch unnecessary.</li>
                  <li>Warning: consider switch if trend or context supports.</li>
                  <li>Unfavorable: switch preferred.</li>
                  <li>Always interpret in context of trends and adherence.</li>
                </ul>
              </div>
              <div class="card deep">
                <h4>Milestones (BCR::ABL1IS)</h4>
                <div class="table-wrap">
                  <table>
                    <thead>
                      <tr>
                        <th>Time</th>
                        <th>Favorable</th>
                        <th>Warning</th>
                        <th>Unfavorable</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td>3 months</td>
                        <td>&lt;= 10%</td>
                        <td>&gt; 10%</td>
                        <td>&gt; 10% if confirmed</td>
                      </tr>
                      <tr>
                        <td>6 months</td>
                        <td>&lt;= 1%</td>
                        <td>&gt; 1â€“10%</td>
                        <td>&gt; 10%</td>
                      </tr>
                      <tr>
                        <td>12 months</td>
                        <td>&lt;= 0.1%</td>
                        <td>&gt; 0.1â€“1%</td>
                        <td>&gt; 1%</td>
                      </tr>
                      <tr>
                        <td>Any time</td>
                        <td>&lt;= 0.1%</td>
                        <td>Loss of MMR</td>
                        <td>Loss of response, resistant mutations, high-risk ACA</td>
                      </tr>
                    </tbody>
                  </table>
                </div>
                <ul>
                  <li>Late responders can still do well; avoid switching on a single value.</li>
                  <li>Unfavorable milestones warrant mutation testing and review of adherence/drug interactions.</li>
                  <li>EMR failure at 3 months is still unfavorable but confirm with repeat sample and context.</li>
                </ul>
              </div>
            </div>
            <div class="check">
              <strong>Quick check</strong>
              <div>What is the 12-month favorable threshold?</div>
              <button class="reveal" data-reveal>Show answer</button>
              <div class="answer">BCR::ABL1IS &lt;= 0.1% (MMR).</div>
            </div>
          </section>

          <section class="module" id="module-6">
            <div class="module-head">
              <h3>Module 6: First-line therapy selection</h3>
              <span class="module-tag">Choose the TKI</span>
            </div>
            <div class="module-grid">
              <div class="card">
                <h4>Core guidance</h4>
                <ul>
                  <li>First-line options: imatinib, dasatinib, nilotinib, bosutinib, asciminib (some countries), radotinib (Korea).</li>
                  <li>2GTKI yield faster/deeper responses vs imatinib, without OS benefit.</li>
                  <li>Goal (OS vs TFR) and comorbidities should guide choice.</li>
                </ul>
              </div>
              <div class="card deep">
                <h4>Comorbidity-driven selection</h4>
                <ul>
                  <li>Pulmonary disease: avoid dasatinib (pleural effusion/PAH risk).</li>
                  <li>GI/renal/hepatic issues: consider avoiding bosutinib.</li>
                  <li>Diabetes or high cardiovascular risk: avoid nilotinib.</li>
                  <li>High ELTS score: consider more potent TKI upfront.</li>
                </ul>
                <p>
                  Asciminib (ASC4FIRST): higher MMR at weeks 48/96 vs investigator choice; fewer grade â‰¥3 AEs and fewer
                  discontinuations; FDA approval for first-line in 2024.
                </p>
              </div>
            </div>
          </section>

          <section class="module" id="module-7">
            <div class="module-head">
              <h3>Module 7: Resistance and mutation-guided therapy</h3>
              <span class="module-tag">Precision switch</span>
            </div>
            <div class="module-grid">
              <div class="card">
                <h4>When to test for mutations</h4>
                <ul>
                  <li>Resistance or warning response.</li>
                  <li>Progression to or presentation in BP.</li>
                  <li>Relapse after alloSCT if prior mutation known.</li>
                  <li>Not recommended after loss of MMR post-TFR.</li>
                </ul>
                <p>Always assess adherence, drug interactions, and TKI exposure before labeling resistance.</p>
              </div>
              <div class="card deep">
                <h4>Key mutation â†’ active TKI (ELN Table 5)</h4>
                <div class="table-wrap">
                  <table>
                    <thead>
                      <tr>
                        <th>Mutation</th>
                        <th>Active TKI</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td>T315I</td>
                        <td>Ponatinib, asciminib</td>
                      </tr>
                      <tr>
                        <td>Y253H</td>
                        <td>Dasatinib, bosutinib, ponatinib, asciminib</td>
                      </tr>
                      <tr>
                        <td>E255K/V</td>
                        <td>Dasatinib, ponatinib, asciminib</td>
                      </tr>
                      <tr>
                        <td>V299L</td>
                        <td>Nilotinib, ponatinib, asciminib</td>
                      </tr>
                      <tr>
                        <td>F317L/V/I/C, T315A</td>
                        <td>Nilotinib, bosutinib, ponatinib, asciminib</td>
                      </tr>
                      <tr>
                        <td>F359V/I/C</td>
                        <td>Dasatinib, ponatinib</td>
                      </tr>
                      <tr>
                        <td>M244V</td>
                        <td>Nilotinib, dasatinib, bosutinib, ponatinib</td>
                      </tr>
                      <tr>
                        <td>A337V/T, L340Q, A344P, A433D, G463D/S, P465S/Q, V468F, F497L, I502L/N, V506L/M</td>
                        <td>Any ATP-competitive TKI</td>
                      </tr>
                    </tbody>
                  </table>
                </div>
              </div>
            </div>
          </section>

          <section class="module" id="module-8">
            <div class="module-head">
              <h3>Module 8: Second-line and beyond</h3>
              <span class="module-tag">Sequencing</span>
            </div>
            <div class="module-grid">
              <div class="card">
                <h4>Second-line guidance</h4>
                <ul>
                  <li>30â€“40% switch from first-line due to intolerance or resistance.</li>
                  <li>Dose reduction is appropriate if response is good and toxicity is manageable.</li>
                  <li>Serious AEs require switching rather than dose reduction.</li>
                </ul>
              </div>
              <div class="card deep">
                <h4>Dose reduction ranges + serious AEs</h4>
                <ul>
                  <li>Imatinib: 400 â†’ 100â€“300 mg daily.</li>
                  <li>Dasatinib: 100 â†’ 20â€“50 mg daily.</li>
                  <li>Nilotinib: 300 mg BID â†’ 150â€“200 mg BID or once daily.</li>
                  <li>Switch for recurrent pleural effusion, PAH, VOE/AOE, enterocolitis, serious neurologic issues, immune-mediated myocarditis/hepatitis/nephritis.</li>
                </ul>
              </div>
            </div>
            <div class="module-grid">
              <div class="card">
                <h4>Beyond second-line</h4>
                <ul>
                  <li>If resistant to 2GTKI: consider early ponatinib or asciminib.</li>
                  <li>ASCEMBL: asciminib superior to bosutinib after â‰¥2 TKIs.</li>
                  <li>OPTIC: dose-optimized ponatinib with reduced AOE risk.</li>
                </ul>
              </div>
              <div class="card deep">
                <h4>Third-line context</h4>
                <p>
                  OPTIC: 45/30/15 mg ponatinib with mandatory reduction to 15 mg once BCR::ABL1IS &lt; 1%. Higher CCyR rates at
                  higher starting dose; AOE rates lower than PACE. Asciminib phase I shows durable MMR with manageable AEs.
                  Olverembatinib (China) active in T315I and multi-TKI resistant CP. Begin donor search at resistance to 2GTKI;
                  refer for transplant at resistance to ponatinib or asciminib.
                </p>
              </div>
            </div>
          </section>

          <section class="module" id="module-9">
            <div class="module-head">
              <h3>Module 9: Advanced phase and blast crisis</h3>
              <span class="module-tag">High urgency</span>
            </div>
            <div class="module-grid">
              <div class="card">
                <h4>Core guidance</h4>
                <ul>
                  <li>Advanced phase is rare in high-income settings but common in delayed diagnosis.</li>
                  <li>Flow cytometry to define BP phenotype; check CNS involvement for lymphoblastic BP.</li>
                  <li>BP treatment: intensive chemo + TKI (dasatinib or ponatinib) â†’ alloSCT if eligible.</li>
                </ul>
              </div>
              <div class="card deep">
                <h4>Clinical nuance</h4>
                <p>
                  Presentation in advanced phase may do better than progression on TKI. Non-eligible patients may receive
                  low-intensity chemo + TKI (clinical trial options emerging).
                </p>
              </div>
            </div>
          </section>

          <section class="module" id="module-10">
            <div class="module-head">
              <h3>Module 10: Allogeneic stem cell transplantation</h3>
              <span class="module-tag">Curative option</span>
            </div>
            <div class="module-grid">
              <div class="card">
                <h4>When to consider alloSCT</h4>
                <ul>
                  <li>CP resistant to 3rd/4th generation TKI or intolerant to all available TKI.</li>
                  <li>Presentation in or progression to BP.</li>
                  <li>Begin donor search at resistance to first 2GTKI.</li>
                </ul>
              </div>
              <div class="card deep">
                <h4>Key points</h4>
                <ul>
                  <li>Outcomes improved with reduced-intensity conditioning and haploidentical donors.</li>
                  <li>Best results in CP1; advanced phase outcomes poorer.</li>
                  <li>Post-alloSCT: q3 monthly molecular monitoring early, then q6 monthly; lifelong follow-up.</li>
                </ul>
              </div>
            </div>
          </section>

          <section class="module" id="module-11">
            <div class="module-head">
              <h3>Module 11: Treatment-free remission (TFR)</h3>
              <span class="module-tag">Stopping safely</span>
            </div>
            <div class="module-grid">
              <div class="card">
                <h4>Core guidance</h4>
                <ul>
                  <li>~40â€“50% can remain off treatment with careful selection.</li>
                  <li>Minimum criteria: â‰¥3 years on TKI and sustained DMR â‰¥1 year.</li>
                  <li>Loss of MMR triggers restart; most regain DMR quickly.</li>
                </ul>
              </div>
              <div class="card deep">
                <h4>ELN TFR requirements (Table 6)</h4>
                <ul>
                  <li>Mandatory: CP1 only, motivated patient, rapid IS monitoring.</li>
                  <li>Minimal: typical e13a2/e14a2 transcripts, TKI &gt;5 years (&gt;4 years for 2GTKI), DMR &gt;2 years.</li>
                  <li>Optimal: DMR &gt;3 years if MR4 or &gt;2 years if MR4.5.</li>
                  <li>Monitoring: 6â€“8 weekly first 6 months, 2-monthly months 6â€“12, then q3â€“6 months.</li>
                </ul>
              </div>
            </div>
          </section>

          <section class="module" id="module-12">
            <div class="module-head">
              <h3>Module 12: Parenting, pregnancy, adverse events</h3>
              <span class="module-tag">Special situations</span>
            </div>
            <div class="module-grid">
              <div class="card">
                <h4>Parenting guidance</h4>
                <ul>
                  <li>Men: no consistent evidence of harm; continue TKI during conception attempts.</li>
                  <li>Women: avoid TKI during pregnancy; IFN is safe; imatinib/nilotinib may be considered after week 16.</li>
                  <li>Breastfeeding: avoid TKI; tailor duration to disease control.</li>
                </ul>
              </div>
              <div class="card deep">
                <h4>Adverse events focus</h4>
                <p>
                  Long-term TKI toxicity management is central: baseline co-morbidity assessment, ongoing surveillance, and
                  proactive adjustment. Notable AE patterns include vascular events (nilotinib/ponatinib), pleural effusion
                  (dasatinib), diarrhea (bosutinib), and metabolic effects. Use Table 8 and monitoring schedule (Table 9) to
                  guide screening.
                </p>
                <div class="table-wrap">
                  <table>
                    <thead>
                      <tr>
                        <th>TKI signal</th>
                        <th>High-yield toxicity</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td>Dasatinib</td>
                        <td>Pleural effusion, PAH</td>
                      </tr>
                      <tr>
                        <td>Nilotinib / Ponatinib</td>
                        <td>Arterial thrombotic events, hypertension, metabolic effects</td>
                      </tr>
                      <tr>
                        <td>Bosutinib</td>
                        <td>Early diarrhea, GI intolerance</td>
                      </tr>
                      <tr>
                        <td>Imatinib</td>
                        <td>Edema, cramps, cytopenias</td>
                      </tr>
                    </tbody>
                  </table>
                </div>
              </div>
            </div>
          </section>

          <div class="cta-band">
            <div>
              <h3>Use this as your ELN 2025 teaching scaffold</h3>
              <p>Jump to any module to teach rounds, update protocols, or onboard trainees.</p>
            </div>
            <button class="cta-primary" data-target="#module-1">Restart from Module 1</button>
          </div>

          <div class="disclaimer">
            Educational summary of published guidance. Not medical advice. Follow institutional protocols and local regulatory
            guidance for patient care.
          </div>
        </div>
      </section>

      <footer class="footer">
        <div>BloodðŸ©¸Doctor Â· Dr Abdul Mannan FRCPath FCPS</div>
        <div>blooddoctor.co@gmail.com</div>
      </footer>
    </div>

    <script>
      const startButton = document.getElementById("startLearning");
      const app = document.getElementById("learningApp");
      const simplifyToggle = document.getElementById("simplifyToggle");

      startButton.addEventListener("click", () => {
        app.classList.remove("is-hidden");
        app.scrollIntoView({ behavior: "smooth", block: "start" });
      });

      simplifyToggle.addEventListener("click", () => {
        const enabled = document.body.classList.toggle("simplify");
        simplifyToggle.setAttribute("aria-pressed", enabled);
        simplifyToggle.textContent = enabled ? "Show deep dive" : "Simplify view";
      });

      document.querySelectorAll("[data-reveal]").forEach((button) => {
        button.addEventListener("click", () => {
          const answer = button.nextElementSibling;
          if (!answer) return;
          answer.classList.toggle("active");
          button.textContent = answer.classList.contains("active") ? "Hide answer" : "Show answer";
        });
      });

      document.querySelectorAll("[data-target]").forEach((button) => {
        button.addEventListener("click", () => {
          const target = document.querySelector(button.dataset.target);
          if (target) target.scrollIntoView({ behavior: "smooth", block: "start" });
        });
      });
    </script>
  </body>
</html>
